US2022072035A1PendingUtilityA1

Pharmaceutical compositions

Assignee: VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTDPriority: Nov 16, 2007Filed: Apr 22, 2021Published: Mar 10, 2022
Est. expiryNov 16, 2027(~1.3 yrs left)· nominal 20-yr term from priority
A61K 47/26A61K 33/26A61K 9/2059A61P 5/18A61K 9/0056A61K 47/02A61P 13/12A61P 3/12A61K 9/2027A61K 9/2018A61P 19/08A61K 9/205A61K 9/009A61K 9/0053A61P 13/00A61K 9/1652A61K 9/2095A61P 7/08A61P 3/00A61K 9/1623A61P 7/00A61K 9/1635A61K 9/70A61K 9/2866
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.

Claims

exact text as granted — not AI-modified
1 . Pharmaceutical composition comprising iron oxy-hydroxide in high loading, in a form suitable for oral administration. 
     
     
         2 . Pharmaceutical composition comprising iron oxy-hydroxide in high loading, in a form suitable for oral administration as film-coated dosage forms for intact swallowing or as dosage forms capable of disintegration in the oral cavity. 
     
     
         3 - 21 . (canceled) 
     
     
         22 . A method for preparing the composition according to  claim 1  in the form of a tablet by direct compression or dry granulation. 
     
     
         23 . A method for preparing the composition according to  claim 1  in the form of a tablet, wherein an aqueous suspension, comprising at least 90% (w/w) of the ingredients based on the total weight of the final composition, is prepared, which is then subjected to spray-drying to obtain a flowable powder, which is optionally mixed with the remaining ingredients and subsequently compressed to obtain a tablet. 
     
     
         24 . A tablet, as obtainable by the method of  claim 23 . 
     
     
         25 . A tablet comprising iron oxy-hydroxide in an amount of 40 to 65% (w/w), saccharose in an amount of 5 to 30% (w/w), and starch in an amount of 5 to 30% (w/w), expressed in relation to the total weight of the tablet composition, excluding the weight of an optionally present tablet coating.

Join the waitlist — get patent alerts

Track US2022072035A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.